Byhealth Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Byhealth kazanç ve gelirin sırasıyla yıllık 34.8% ve 11.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 34.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 11.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

34.8%

Kazanç büyüme oranı

34.8%

EPS büyüme oranı

Personal Products kazanç büyümesi	25.7%
Gelir büyüme oranı	11.8%
Gelecekteki özkaynak getirisi	11.5%
Analist kapsamı	Good
Son güncelleme	07 Nov 2024

Gelecekteki son büyüme güncellemeleri

Byhealth Co., Ltd (SZSE:300146) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 23

Recent updates

Byhealth Co., Ltd (SZSE:300146) Surges 32% Yet Its Low P/E Is No Reason For Excitement

Sep 30

Byhealth Co., Ltd (SZSE:300146) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 23

Kazanç ve Gelir Büyüme Tahminleri

SZSE:300146 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	9,347	1,528	1,329	1,631	9
12/31/2025	8,469	1,295	590	1,357	10
12/31/2024	7,162	798	-625	1,010	7
9/30/2024	7,358	714	739	1,046	N/A
6/30/2024	8,424	1,092	995	1,306	N/A
3/31/2024	8,945	1,443	223	1,535	N/A
12/31/2023	9,407	1,746	794	2,051	N/A
9/30/2023	9,484	1,805	666	1,938	N/A
6/30/2023	9,237	1,883	818	2,075	N/A
3/31/2023	8,689	1,752	1,833	2,090	N/A
12/31/2022	7,861	1,386	1,134	1,379	N/A
9/30/2022	7,563	1,573	1,404	1,645	N/A
6/30/2022	7,454	1,431	1,170	1,430	N/A
3/31/2022	7,489	1,601	1,468	1,721	N/A
12/31/2021	7,431	1,754	1,556	1,819	N/A
9/30/2021	7,091	1,720	1,000	1,267	N/A
6/30/2021	7,168	1,934	1,299	1,534	N/A
3/31/2021	6,822	1,806	1,236	1,573	N/A
12/31/2020	6,095	1,524	1,245	1,566	N/A
9/30/2020	5,914	-80	1,733	2,039	N/A
6/30/2020	5,417	-261	1,485	1,821	N/A
3/31/2020	5,186	-319	1,319	1,576	N/A
12/31/2019	5,262	-356	1,205	1,537	N/A
9/30/2019	5,310	1,132	880	1,192	N/A
6/30/2019	5,151	1,161	974	1,238	N/A
3/31/2019	4,854	1,125	905	1,234	N/A
12/31/2018	4,351	999	1,098	1,349	N/A
9/30/2018	4,182	1,018	968	1,226	N/A
6/30/2018	3,794	885	N/A	1,084	N/A
3/31/2018	3,442	852	N/A	951	N/A
12/31/2017	3,111	763	N/A	954	N/A
9/30/2017	2,747	771	N/A	809	N/A
6/30/2017	2,562	759	N/A	772	N/A
3/31/2017	2,389	594	N/A	694	N/A
12/31/2016	2,309	535	N/A	685	N/A
9/30/2016	2,398	619	N/A	710	N/A
6/30/2016	2,322	577	N/A	583	N/A
3/31/2016	2,344	655	N/A	613	N/A
12/31/2015	2,266	635	N/A	635	N/A
9/30/2015	2,101	609	N/A	606	N/A
6/30/2015	1,944	566	N/A	624	N/A
3/31/2015	1,806	530	N/A	572	N/A
12/31/2014	1,705	503	N/A	561	N/A
9/30/2014	1,704	547	N/A	674	N/A
6/30/2014	1,668	542	N/A	764	N/A
3/31/2014	1,594	481	N/A	707	N/A
12/31/2013	1,482	422	N/A	627	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 300146 'nin tahmini kazanç büyümesi (yıllık 34.8% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 300146 şirketinin kazançlarının (yıllık 34.8% ) CN pazarından (yıllık 26.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 300146 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: 300146 şirketinin gelirinin (yıllık 11.8% ) CN pazarından (yıllık 13.9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 300146 şirketinin gelirinin (yıllık 11.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 300146 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 11.5 %).

Byhealth Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates fall by 15%

Consensus revenue estimates fall by 18%

Price target decreased by 10% to CN¥19.91

Byhealth Co., Ltd (SZSE:300146) Just Reported Earnings, And Analysts Cut Their Target Price

Price target decreased by 8.9% to CN¥24.05

Price target decreased by 7.7% to CN¥26.37

Recent updates

Consensus revenue estimates fall by 15%

Third quarter 2024 earnings released: CN¥0.013 loss per share (vs CN¥0.21 profit in 3Q 2023)

Investor sentiment deteriorates as stock falls 20%

Byhealth Co., Ltd (SZSE:300146) Surges 32% Yet Its Low P/E Is No Reason For Excitement

Byhealth Co., Ltd to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 17%

Byhealth (SZSE:300146) Will Want To Turn Around Its Return Trends

Consensus revenue estimates fall by 18%

Things Look Grim For Byhealth Co., Ltd (SZSE:300146) After Today's Downgrade

Price target decreased by 10% to CN¥19.91

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.095 (vs CN¥0.30 in 2Q 2023)

Investors Don't See Light At End Of Byhealth Co., Ltd's (SZSE:300146) Tunnel

Byhealth Co., Ltd to Report First Half, 2024 Results on Aug 06, 2024

Byhealth (SZSE:300146) Could Be Struggling To Allocate Capital

First quarter 2024 earnings released: EPS: CN¥0.43 (vs CN¥0.61 in 1Q 2023)

Byhealth Co., Ltd Approves Cash Dividend for the Year 2023

Byhealth Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

We Think That There Are Issues Underlying Byhealth's (SZSE:300146) Earnings

Byhealth Co., Ltd (SZSE:300146) Just Reported Earnings, And Analysts Cut Their Target Price

Byhealth Co., Ltd Announces Profit Distribution Proposal for 2023

Byhealth Co., Ltd, Annual General Meeting, Apr 11, 2024

Price target decreased by 8.9% to CN¥24.05

Full year 2023 earnings released: EPS: CN¥1.03 (vs CN¥0.82 in FY 2022)

Now 21% overvalued

Byhealth Co., Ltd to Report Fiscal Year 2023 Results on Mar 19, 2024

Price target decreased by 7.7% to CN¥26.37

Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.25 in 3Q 2022)

Provexis plc Announces Byhealth Co., Ltd Regulatory Filing with Chinese SAMR

High number of new directors

Byhealth Co. Ltd. Approves Executive Appointments

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.23 in 2Q 2022)

Byhealth Co., Ltd to Report First Half, 2023 Results on Aug 05, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased to CN¥27.71

Third quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.17 in 3Q 2021)

Consensus EPS estimates fall by 14%

Price target decreased to CN¥29.08

Second quarter 2022 earnings released

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

By-Health Co., Ltd. Implements Cash Dividend for 2021, Payable on 13 April 2022

By-Health Co., Ltd. Approves Cash Dividend for 2021

By-health Co., Ltd. Proposes Cash Dividend for 2021

Full year 2021 earnings: EPS exceeds analyst expectations

Price target decreased to CN¥32.67

Price target decreased to CN¥33.98

Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.32 in 3Q 2020)

Investor sentiment deteriorated over the past week

Price target increased to CN¥36.49

Price target increased to CN¥34.07

First quarter 2021 earnings released: EPS CN¥0.52 (vs CN¥0.34 in 1Q 2020)

Investor sentiment improved over the past week

By-health Co., Ltd., Annual General Meeting, Mar 26, 2021

New 90-day high: CN¥28.08

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥0.24 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Price target raised to CN¥31.56

New 90-day low: CN¥22.89

By-health Co., Ltd. to Report Fiscal Year 2020 Results on Mar 06, 2021

New 90-day high: CN¥25.87

Third quarter earnings released

By-health Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

By-health Co., Ltd. Announces Management Appointment

Price target raised to CN¥26.23

Price target raised to CN¥24.38

New 90-day high - CN¥22.58

By-health Co., Ltd. to Report First Half, 2020 Results on Jul 30, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri